AMAG Spends $700 Million To Better Sell Makena
This article was originally published in The Pink Sheet Daily
Purchase of Cord Blood Registry is expected to boost commercialization of preterm birth drug Makena, while adding a stable growth business to AMAG and offering cost synergies.
You may also be interested in...
The controversies have shown that, while it may be easy to scapegoat outliers, it is remarkably hard to lower a drug price by political fiat. It took a while, but now Makena, Daraprim and Acthar are all facing very different days of reckoning.
Subgroup analyses by AMAG may support ongoing use, but the once-controversial Makena seems unlikely to be pulled from the US market in any event since compounded progesterone is the only alternative therapy.
KV clears major hurdle as court okays its chapter 11 reorganization plan, which provides for payment of $23.4 million owed under 2010 Department of Justice settlement and $231.4 million for senior notes; firm’s future remains tied to Makena.